## MDT: Medtronic plc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -3.1% below STRENGTH zone (4.0-10.0%); PEG 2.32 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-4.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($95.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Medtronic PLC $MDT Shares Sold by Intrepid Family Office LLC**
- Source: MarketBeat | 20251209T140823 | Somewhat-Bullish | Relevance: 99%
-  Intrepid Family Office LLC decreased its stake in Medtronic PLC (NYSE:MDT) by 25% in the second quarter, selling 10,000 shares and retaining 30,000 shares valued at $2.615 million. The medical technology company exceeded quarterly earnings and revenue estimates and announced a quarterly dividend of $0.71 per share. Analysts generally rate Medtronic as a "Moderate Buy" with a consensus price target of $110.44.

**2. First Trust Advisors LP Sells 103,019 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T111333 | Somewhat-Bullish | Relevance: 98%
-  First Trust Advisors LP reduced its holdings in Medtronic PLC by 10.9%, selling 103,019 shares and retaining 841,814 shares. Medtronic reported stronger-than-expected quarterly earnings and revenue, with FY2026 guidance set at $5.620-$5.660 EPS, and announced a quarterly dividend of $0.71. The stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44.

**3. Medtronic changes investor relations leadership ahead of diabetes spinout**
- Source: MedTech Dive | 20251209T154026 | Neutral | Relevance: 98%
-  Medtronic has announced a change in its investor relations leadership in preparation for the spin-off of its diabetes division, MiniMed. Ryan Weispfenning, formerly head of investor relations at Medtronic, will now establish and lead the investor relations function at the new standalone MiniMed company. Ingrid Goldberg has been hired to replace Weispfenning at Medtronic.

**4. California Public Employees Retirement System Purchases 563,779 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251207T100754 | Bullish | Relevance: 98%
- The California Public Employees Retirement System (CalPERS) significantly increased its stake in Medtronic PLC, purchasing 563,779 additional shares in Q2 2025, bringing its total holdings to 3,230,852 shares valued at approximately $281.6 million. Medtronic stock currently holds a "Moderate Buy" consensus rating from analysts with an average price target of $110.44. The company recently surpassed quarterly earnings and revenue estimates and announced a quarterly dividend, indicating strong financial health and positive outlook.

**5. Thematics Asset Management Sells 13,298 Shares of Medtronic PLC $MDT**
- Source: MarketBeat | 20251208T121527 | Bullish | Relevance: 98%
-  Thematics Asset Management reduced its stake in Medtronic PLC by selling 13,298 shares, now holding 184,899 shares valued at $16.12 million; however, many other institutional investors increased their positions. Medtronic reported strong quarterly earnings, beating analyst estimates for EPS and revenue, and announced a quarterly dividend of $0.71. The company's stock has also received updated price targets and ratings from several analyst firms.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 9, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Barclays | $111 | $109 | +2% |
| 2025-11-20 | Truist Securiti | $110 | $103 | +7% |
| 2025-11-19 | Morgan Stanley | $117 | $107 | +9% |
| 2025-11-19 | RBC Capital | $118 | $111 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Barclays | main | Overweight |
| 2025-11-20 | Truist Securiti | main | Hold |
| 2025-11-19 | Morgan Stanley | main | Overweight |
| 2025-11-19 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 43.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 9.9% (+0.1%)
- Blackrock Inc.: 9.3% (-2.4%)
- JPMORGAN CHASE & CO: 8.1% (+197.7%)
- State Street Corpora: 4.7% (+1.1%)
- Capital Research Glo: 2.4% (-15.6%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-4.5% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 9 raises (avg +11%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 2.32 elevated, pricing in significant growth expectations. Balance sheet: strong liquidity (2.4x). Analyst sentiment positive (9 raises, avg +11%). Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $127.8B |
| Beta | 0.72 |
| 52W Range | $79.29 - $106.33 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 2.32 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 8.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.4% to -3.1% (-4.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.1pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.10x) but short-term weakness (below SMA20). RSI neutral at 51.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -3.09% (CS: 34) | Weak |
| RSI_14 | 50.9 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.990x | Below |
| vs SMA50 | 1.029x | Above |
| vs SMA200 | 1.096x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $99.62
- **Stop Loss:** $95.90 (3.7% risk)
- **Target:** $103.34 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 80
- **Position Value:** $7,969.60
- **Portfolio %:** 7.97%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-17 (Est: $1.34)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $1.31 | $1.36 | +3.5% |
| 2025Q3 | $1.23 | $1.26 | +2.5% |
| 2025Q2 | $1.58 | $1.62 | +2.7% |
| 2025Q1 | $1.36 | $1.39 | +2.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*